Top

BMC Cancer

Published in:

Open Access 01-12-2018 | Research article

The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens

Authors: Zhipeng Mai, Zhien Zhou, Weigang Yan, Yu Xiao, Yi Zhou, Zhiyong Liang, Zhigang Ji, Hanzhong Li

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

Prostate biopsy is the most common method for the diagnosis of prostate cancer and the basis for further treatment. Confirmation using radical prostatectomy specimens is the most reliable method for verifying the accuracy of template-guided transperineal prostate biopsy. The study aimed to reveal the spatial distribution of prostate cancer in template-guided transperineal saturation biopsy and radical prostatectomy specimens.

Methods

Between December 2012 to December 2016, 171 patients were diagnosed with prostate cancer via template-guided transperineal prostate biopsy and subsequently underwent laparoscopic radical prostatectomy. The spatial distributions of prostate cancer were analyzed and the consistency of the tumor distribution between biopsy and radical prostatectomy specimens were compared.

Results

The positive rate of biopsy in the apex region was significantly higher than that of the other biopsy regions (43% vs 28%, P < 0.01). In radical prostatectomy specimens, the positive rate was highest at the region 0.9–1.3 cm above the apex, and it had a tendency to decrease towards the base. There was a significant difference in the positive rate between the cephalic and caudal half of the prostate (68% vs 99%, P < 0.01). There were no significant differences between the anterior and posterior zones for either biopsy or radical prostatectomy specimens.

Conclusion

The tumor spatial distribution generated by template-guided transperineal prostate biopsy was consistent with that of radical prostatectomy specimens in general. The positive rate was consistent between anterior and posterior zones. The caudal half of the prostate, especially the vicinity of the apex, was the frequently occurred site of the tumor.

Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, Bottomley D, Eggener S, Ehdaie B, Emberton M, et al. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. Eur Urol. 2015;67(4):771–7.CrossRefPubMedPubMedCentral

Merrick GS, Delatore A, Butler WM, Bennett A, Fiano R, Anderson R, Adamovich E. Transperineal template-guided mapping biopsy identifies pathologic differences between very-low-risk and low-risk prostate cancer: implications for active surveillance. Am J Clin Oncol. 2015;40(1):53–9.CrossRef

Chang DT, Challacombe B, Lawrentschuk N. Transperineal biopsy of the prostate--is this the future? Nat Rev Urol. 2013;10(12):690–702.CrossRefPubMed

Mai Z, Yan W, Zhou Y, Zhou Z, Chen J, Xiao Y, Liang Z, Ji Z, Li H. Transperineal template-guided prostate biopsy: 10 years of experience. BJU Int. 2016;117(3):424–9.CrossRefPubMed

Yan W, Li H, Zhou Y, Huang Z, Rong S, Xia M, Ji Z, Chen J, Jiang Y. Prostate carcinoma spatial distribution patterns in Chinese men investigated with systematic transperineal ultrasound guided 11-region biopsy. Urol Oncol. 2009;27(5):520–4.CrossRefPubMed

Li H, Yan W, Zhou Y, Ji Z, Chen J. Transperineal ultrasound-guided saturation biopsies using 11-region template of prostate: report of 303 cases. Urology. 2007;70(6):1157–61.CrossRefPubMed

Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013;73(7):778–87.CrossRefPubMed

D’Amico AV, Davis A, Vargas SO, Renshaw AA, Jiroutek M, Richie JP. Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated? Int J Radiat Oncol Biol Phys. 1999;43(3):587–90.CrossRefPubMed

Perera M, Lawrentschuk N, Bolton D, Clouston D. Comparison of contemporary methods for estimating prostate tumour volume in pathological specimens. BJU Int. 2014;113(Suppl 2):29–34.CrossRefPubMed

10.

Richters A, Derks J, Husson O, Van Onna IEW, Fossion LMCL, Kil PJM, Verhoeven RHA, Aarts MJ. Effect of surgical margin status after radical prostatectomy on health-related quality of life and illness perception in patients with prostate cancer. Urol Oncol. 2015;33(1):16.e9–16.e15.CrossRef

11.

Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017;18(2):181–91.CrossRefPubMed

12.

Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012;13(6):622–32.CrossRefPubMedPubMedCentral

13.

Ahmed HU, Dickinson L, Charman S, Weir S, McCartan N, Hindley RG, Freeman A, Kirkham AP, Sahu M, Scott R, et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol. 2015;68(6):927–36.CrossRefPubMed

14.

Singh PB, Anele C, Dalton E, Barbouti O, Stevens D, Gurung P, Arya M, Jameson C, Freeman A, Emberton M, et al. Prostate Cancer tumour features on template prostate-mapping biopsies: implications for focal therapy. Eur Urol. 2014;66(1):12–9.CrossRefPubMedPubMedCentral

15.

Sivaraman A, Barret E. Focal therapy for prostate cancer: an “à la carte” approach. Eur Urol. 2016;69(6):973–5.CrossRefPubMed

16.

Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 1997;20(5):680–8.CrossRef

17.

Bittner N, Merrick GS, Butler WM, Bennett A, Galbreath RW. Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy. J Urol. 2013;190(2):509–14.CrossRefPubMed

18.

Bott SR, Young MP, Kellett MJ, Parkinson MC. Contributors to the UCL Hospitals’ Trust Radical Prostatectomy Database. Anterior prostate cancer: is it more difficult to diagnose? BJU Int. 2002;89(9):886–9.CrossRefPubMed

19.

Furuno T, Demura T, Kaneta T, Gotoda H, Muraoka S, Sato T, Nagamori S, Shinohara N, Koyanagi T. Difference of cancer core distribution between first and repeat biopsy: in patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. Prostate. 2004;58(1):76–81.CrossRefPubMed

20.

Kido M, Hitosugi M, Ishii K, Kamimura S, Joh K. Latent prostate cancer in Japanese men who die unnatural deaths: a forensic autopsy study. Prostate. 2015;75(9):917–22.CrossRefPubMed

21.

Huo AS, Hossack T, Symons JL, PeBenito R, Delprado WJ, Brenner P, Stricker PD. Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens. J Urol. 2012;187(6):2044–9.CrossRefPubMed

22.

Zhang Q, Wang W, Zhang B, Shi J, Fu Y, Li D, Guo S, Zhang S, Huang H, Jiang X, et al. Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China. Int Urol Nephrol. 2017;49(3):439–48.CrossRefPubMed

23.

Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M, Palmer S, Matsugasumi T, Marien A, Bernhard JC, et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol. 2015;67(4):787–94.CrossRefPubMed

24.

Gordetsky J, Rais-Bahrami S, Epstein JI. Pathological findings in multiparametric magnetic resonance imaging/ultrasound fusion-guided biopsy: relation to prostate cancer focal therapy. Urology. 2017;105:18–23.CrossRefPubMed

25.

van de Ven WJ, Venderink W, Sedelaar JP, Veltman J, Barentsz JO, Futterer JJ, Cornel EB, Huisman HJ. MR-targeted TRUS prostate biopsy using local reference augmentation: initial experience. Int Urol Nephrol. 2016;48(7):1037–45.CrossRefPubMedPubMedCentral

Title: The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens
Authors: Zhipeng Mai
Zhien Zhou
Weigang Yan
Yu Xiao
Yi Zhou
Zhiyong Liang
Zhigang Ji
Hanzhong Li
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-5124-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Laparoscopy-assisted colectomy as an Oncologically safe alternative for patients with stage T4 Colon Cancer: a propensity-matched cohort study

Detection of mutations in SF3B1, EIF1AX and GNAQ in primary orbital melanoma by candidate gene analysis

Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

Investigation of the SLC22A23 gene in laryngeal squamous cell carcinoma

Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer